MARKET

PFE

PFE

Pfizer
NYSE
27.75
-0.03
-0.11%
After Hours: 27.76 +0.01 +0.04% 19:59 03/28 EDT
OPEN
27.82
PREV CLOSE
27.78
HIGH
28.12
LOW
27.72
VOLUME
40.47M
TURNOVER
0
52 WEEK HIGH
42.22
52 WEEK LOW
25.38
MARKET CAP
157.14B
P/E (TTM)
74.76
1D
5D
1M
3M
1Y
5Y
Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
Seeking Alpha · 11h ago
BetterInvesting™ Magazine Update on Paychex Inc. and Pfizer Inc.
BetterInvesting Magazine announces Paychex Inc. As its "Stock to Study" in the June/July 2024 issue for investors' informational and educational use. Pfizer Inc. Is also named as the magazine's "Undervalued Stock" for the same issue. The magazine reminds investors to focus on the fundamentals of individual companies.
PR Newswire · 11h ago
Pfizer, Astellas first-line bladder cancer therapy accepted for review in China
Astellas co-develops Padcev with Pfizer as a first-line bladder cancer therapy accepted for review in China. Chinese regulators agreed to review a request to expand the label of the drug. If approved, the drug will offer a new treatment regimen for certain patients with bladder cancer.
Seeking Alpha · 17h ago
May 10th Options Now Available For Pfizer (PFE)
NASDAQ · 18h ago
5 Stocks Yielding 5% To Beat The Looming Retirement Crisis
Retirement crisis is looming as many people are unprepared for retirement and worry about inflation's impact on savings. BlackRock CEO Larry Fink suggests policymakers improve retirement systems and invest in energy infrastructure to address the crisis. Investing in undervalued stocks with solid balance sheets and dividend growth can offer a pathway to building a resilient retirement portfolio. Vladislav Stepanov discusses 5 stocks investors may consider for investment.
Seeking Alpha · 21h ago
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
NASDAQ · 1d ago
Giverny Capital Rochon Global Portfolio 2023 Annual Letter To Partners
Giverny Capital Rochon Global Portfolio 2023 Annual Letter To Partners. Giverny is a Montreal-based investment advisor specializing in private wealth management. The company has managed a family portfolio since 1993. Since its inception in 1993, the GivernY portfolio has had a compounded annual return of 14.8%.
Seeking Alpha · 1d ago
Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?
NASDAQ · 1d ago
More
About PFE
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Webull offers Pfizer Inc stock information, including NYSE: PFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PFE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PFE stock methods without spending real money on the virtual paper trading platform.